Renogen is developed by National Kidney and Transplant Institute, Philippines.

What development phase is Renogen in?

Renogen is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Renogen

National Kidney and Transplant Institute, Philippines · FDA-approved active Small molecule Quality 0/100

Renogen, marketed by the National Kidney and Transplant Institute in the Philippines, holds a unique position in the renal therapy market. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its competitive edge. However, the lack of detailed clinical trial results and revenue data poses a significant risk in assessing its long-term market sustainability.

At a glance

Generic name	Renogen
Also known as	Epoietin Alpha
Sponsor	National Kidney and Transplant Institute, Philippines
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Effect on Vascular Reactivity Using the Erythropoeitin Alpha on Incident Peritoneal Dialysis Patients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results